Pfenex elects Eef Schimmelpennink as CEO.
M2 PHARMA-August 3, 2017-Pfenex elects Eef Schimmelpennink as CEO
(C)2017 M2 COMMUNICATIONS
Biotechnology company Pfenex Inc (NYSE MKT:PFNX) reported on Wednesday the appointment of Evert (Eef) Schimmelpennink as its chief executive officer, president, and secretary with immediate effect.
Also effective 3 August 2017, Schimmelpennink has been elected to serve as a Class III member of the board of directors.
In conjunction, Patrick Lucy, the company's interim chief executive officer, president and secretary, will continue to serve in his role as chief business officer.
Most recently, Schimmelpennink has served as the chief executive officer of Alvotech, a biosimilar development company. Previously, Schimmelpennink was employed as vice president Global Injectables at Pfizer as well as vice president - Global Generics of Hospira.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 3, 2017|
|Previous Article:||Haldex's board unanimously decides not to support Knorr-Bremse takeover offer.|
|Next Article:||Emmes Wins USD 70m National Institutes of Health Contract for Pediatric Research.|